Semaglutide is an independently verified agonist at the glucagon-like peptide-1 receptor (GLP-1R). It is one of the most widely referenced incretin research compounds in the current literature, and it is the single-receptor baseline against which the dual- and triple-agonist constructs are usually compared.
Structurally it is a 31-amino-acid analog of native glucagon-like peptide-1 (7-37), modified at two positions for enzymatic stability and carrying a fatty-diacid side chain that binds serum albumin. That conjugation is what extends its plasma half-life by roughly two orders of magnitude over the native peptide, which is why it behaves as a long-acting tool compound in research models rather than a minutes-scale one.
Vantage lists this compound under the catalog name VA-1S. The catalog
name and the vial label use the short form; the compound is semaglutide, and this page is the
reference record for it.
Verified compound data
| Property | Value |
|---|---|
| Compound name | Semaglutide |
| Catalog name | VA-1S |
| CAS number | 910463-68-2 |
| PubChem CID | 56843331 |
| Molecular formula | C187H291N45O59 |
| Molecular weight | ~4114 g/mol |
| Length | 31 residues |
| Physical form | Lyophilized powder, or pre-formulated solution in a sealed research pen |
Molecular formula, molecular weight and registry data verified against PubChem
(CID 56843331).
Research-context mechanism
In the preclinical literature semaglutide is characterised as a potent, selective full agonist at GLP-1R, a class B G-protein-coupled receptor. Receptor occupancy drives Gs coupling, adenylate cyclase activation and a rise in intracellular cAMP, with downstream PKA and Epac2 signaling. It is used as a reference agonist in islet, hepatocyte and neuronal culture systems, and as the comparator arm in studies characterising newer multi-receptor constructs.
These mechanisms are described strictly as they appear in in vitro and animal research
models. They are not established human-use mechanisms, and nothing on this page describes an
approved therapeutic use, an outcome, or a protocol.
Current research summary
- GLP-1 receptor binding affinity and downstream cAMP/PKA signaling
- Pancreatic islet and beta-cell secretory models
- Receptor internalisation, recycling and biased-agonism studies
- Hypothalamic and brainstem neuroendocrine signaling pathways
- Comparative incretin pharmacology: mono-agonist versus dual- and triple-agonist constructs
- Peptide stability, albumin binding and half-life extension chemistry
How identity and purity are verified
Every lyophilized lot Vantage publishes carries a batch Certificate of Analysis on its own
product page, showing the HPLC purity result and the mass-spectrometry identity result for
that specific lot. The certificate is issued by the manufacturer’s contract laboratory.
Vantage describes it as a batch COA and makes no claim of buyer-contracted independent
testing.
Purity publishes at the site specification of 98% or greater by HPLC. Mass-spectrometry
identity is reported against the compound’s own theoretical mass, which for semaglutide is
approximately 4114 g/mol as listed in the table above. Where a lot has no certificate on
file, no certificate is shown and no testing claim is made for it.
The certificate for the current lot is published on the product page:
VA-1S, 5mg lyophilized vial. The pre-formulated research pen is a
separate listing at VA-1S Pen; pens are supplied as a
sealed pre-formulated solution and do not carry a lot certificate.
Frequently Asked Questions
What is semaglutide?
Semaglutide is a synthetic 31-amino-acid analog of glucagon-like peptide-1, acting as a long-acting agonist at the GLP-1 receptor. It is studied in preclinical receptor-signaling and islet research models, is supplied as a lyophilized powder, and is not approved for human use.
What is the molecular formula of semaglutide?
The molecular formula of semaglutide is C187H291N45O59, with a molecular weight of approximately 4114 g/mol (PubChem CID 56843331).
What is the CAS number for semaglutide?
The CAS registry number for semaglutide is 910463-68-2.
Is VA-1S the same compound as semaglutide?
Yes. VA-1S is the Vantage catalog name for semaglutide. The catalog name and the vial label use the short form; the compound supplied is semaglutide, and its identity is confirmed on the batch Certificate of Analysis for each lot.
Is semaglutide approved for human use?
No. Semaglutide is not supplied as an approved drug and is not intended for human consumption. It is offered strictly as a research compound for laboratory use.
Does each semaglutide lot come with a COA?
Yes. Every lyophilized lot carries a batch Certificate of Analysis published on its product page, reporting HPLC purity and mass-spectrometry identity for that specific lot against the theoretical mass of approximately 4114 g/mol.
Related references
Vantage documents the other incretin-pathway compounds in its catalog at
semaglutide, tirzepatide and
retatrutide. All are listed under
incretin receptor agonists.
For research use only. Not for human or veterinary use. Not approved by the FDA. 21+
- HPLC + MS tested, on tested lots
- U.S. synthesized
- Batch COA on the pages that carry one